Experimental Hematology
Volume 35, Issue 4 , Pages 618-626 , April 2007

The role of Wilms' tumor gene peptide–specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone

  • Kazuhiko Ikeda

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan
    • ,
  • Tsutomu Shichishima

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan
    • Fukushima Research Institute of Environment and Medicine, Fukushima, Japan
    • Corresponding Author InformationOffprint requests to: Tsutomu Shichishima, M.D., Ph.D., First Department of Internal Medicine, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima 960-1295, Japan
    • ,
  • Masaki Yasukawa

      Affiliations

    • First Department of Internal Medicine, Ehime University School of Medicine, Ehime, Japan
    • ,
  • Akiko Nakamura-Shichishima

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan
    • ,
  • Hideyoshi Noji

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan
    • ,
  • Kazuko Akutsu

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan
    • ,
  • Kazuoki Osumi

      Affiliations

    • Otsuka Life Science Initiative, Otsuka Pharmaceutical Initiative, Tokyo, Japan
    • ,
  • Yukio Maruyama

      Affiliations

    • First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan

Received 2 June 2006 ,Revised 29 December 2006 ,Accepted 19 January 2007.

References 

  1. Rosse WF, Parker CJ. Paroxysmal nocturnal haemoglobinuria. Clin Haematol. 1985;14:105–125
  2. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–1258
  3. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–3709
  4. Young NS. The problem of clonality in aplastic anemia: Dr. Dameshek's riddle, restated. Blood. 1992;79:1385–1392
  5. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A. 1983;80:5066–5070
  6. Shichishima T, Terasawa T, Hashimoto C, Ohto H, Uchida T, Maruyama Y. Heterogeneous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes. Br J Haematol. 1991;78:545–550
  7. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–711
  8. Kawagoe K, Kitamura D, Okabe M, et al. Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. Blood. 1996;87:3600–3606
  9. Yamamoto T, Shichishima T, Shikama Y, Saitoh Y, Ogawa K, Maruyama Y. Granulocytes from patients with paroxysmal nocturnal hemoglobinuria and normal individuals have the same sensitivity to spontaneous apoptosis. Exp Hematol. 2002;30:187–194
  10. Kulkarni S, Bessler M. The effect of GPI-anchor deficiency on apoptosis in mice carrying a Piga gene mutation in hematopoietic cells. J Leukoc Biol. 2002;72:1228–1233
  11. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84:4257–4261
  12. Maciejewski JP, Follmann D, Nakamura R, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood. 2001;98:3513–3519
  13. Shichishima T, Okamoto M, Ikeda K, et al. HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:22–28
  14. Okamoto M, Shichishima T, Noji H, et al. High frequency of several PIG-A mutations in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2006;20:627–634
  15. Shichishima T, Noji H, Ikeda K, Akutsu K, Maruyama Y. The frequency of HLA class I alleles in Japanese patients with bone marrow failure. Haematologica. 2006;91:856–857
  16. Zeng W, Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest. 2001;108:765–773
  17. Plasilova M, Risitano AM, O'Keefe CL, et al. Shared and individual specificities of immunodominant cytotoxic T-cell clones in paroxysmal nocturnal hemoglobinuria as determined by molecular analysis. Exp Hematol. 2004;32:261–269
  18. Nakao S, Yamaguchi M, Shiobara S, et al. Interferon-gamma gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia. Blood. 1992;79:2532–2535
  19. Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol. 1996;3:101–110
  20. Young NS, Maciejewski JP. Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes “Why? Why? Why?”. J Clin Invest. 2000;106:637–641
  21. Karadimitris A, Notaro R, Koehne G, Roberts IA, Luzzatto L. PNH cells are as sensitive to T-cell-mediated lysis as their normal counterparts: implications for the pathogenesis of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2000;111:1158–1163
  22. Kai T, Shichishima T, Noji H, et al. Phenotypes and phosphatidylinositol glycan–class A gene abnormalities during cell differentiation and maturation from precursor cells to mature granulocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:3812–3818
  23. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 2000;51:99–107
  24. Ohminami H, Yasukawa M, Fujita S. HLA class I–restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286–293
  25. Koesters R, Linnebacher M, Coy JF, et al. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer. 2004;109:385–392
  26. Doubrovina ES, Doubrovin MM, Lee S, et al. In vitro stimulation with WT1 peptide–loaded Epstein-Barr virus–positive B cells elicits high frequencies of WT1 peptide–specific T cells with in vitro and in vivo tumoricidal activity. Clin Cancer Res. 2004;10:7207–7219
  27. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia. 1999;13:393–399
  28. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071–3079
  29. Lyakisheva A, Felda O, Ganser A, Schmidt RE, Schubert J. Paroxysmal nocturnal hemoglobinuria: Differential gene expression of EGR-1 and TAXREB107. Exp Hematol. 2002;30:18–25
  30. Heeney MM, Ormsbee SM, Moody MA, Howard TA, DeCastro CM, Ware RE. Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria. Mol Genet Metab. 2003;78:291–294
  31. Inoue N, Murakami Y, Kinoshita T. Molecular genetics of paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2003;77:107–112
  32. Tsuji T, Yasukawa M, Matsuzaki J, et al. Generation of tumor-specific, HLA class I–restricted human Th1 and Tc1 cells by cell engineering with tumor peptide–specific T-cell receptor genes. Blood. 2005;106:470–476
  33. Shichishima T, Terasawa T, Saitoh Y, Hashimoto C, Ohto H, Maruyama Y. Diagnosis of paroxysmal nocturnal haemoglobinuria by phenotypic analysis of erythrocytes using two-colour flow cytometry with monoclonal antibodies to DAF and CD59/MACIF. Br J Haematol. 1993;85:378–386
  34. Lewis SM, Dacie JV. The aplastic anaemia–paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol. 1967;13:236–251
  35. Sugita Y, Nakano Y, Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem. 1988;104:633–637
  36. Shichishima T, Terasawa T, Uchida T, Kariyone S. Complement sensitivity of erythroblasts and erythropoietic precursors in paroxysmal nocturnal haemoglobinuria (PNH). Br J Haematol. 1989;72:578–583
  37. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94–96
  38. Bodinier M, Peyrat MA, Tournay C, et al. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat Med. 2000;6:707–710
  39. Karanikas V, Lurquin C, Colau D, et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant Canarypox virus. J Immunol. 2003;171:4898–4904
  40. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102:2892–2900
  41. Rezvani K, Brenchley JM, Price DA, et al. T-cell responses directed against multiple HLA-A∗0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res. 2005;11:8799–8807
  42. Azuma T, Otsuki T, Kuzushima K, Froelich CJ, Fujita S, Yasukawa M. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res. 2004;10:7402–7412
  43. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100:2132–2137
  44. Amrolia PJ, Reid SD, Gao L, et al. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood. 2003;101:1007–1014
  45. Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood. 2002;99:3272–3279
  46. Howe EC, Wlodarski M, Ball EJ, Rybicki L, Maciejewski JP. Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes. Exp Hematol. 2005;33:1357–1362
  47. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol. 2001;73:177–187

PII: S0301-472X(07)00056-2

doi: 10.1016/j.exphem.2007.01.045

Experimental Hematology
Volume 35, Issue 4 , Pages 618-626 , April 2007

Article Tools

* Image Usage & Resolution